Aspirin Twice a Day in Patients With Diabetes and Acute Coronary Syndrome

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2484 participants.

Also called NCT02520921

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,484 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02520921
  • EudraCT 2015-000947-18
Other papers using this trial's data
  • Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial European heart journal, 2026-02-11 DOI, PubMed 40884757

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
France (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02520921. Randomized; no masking; primary purpose treatment. Start 2016-06-13 (actual); primary completion 2024-07-18 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Aspirin Twice a Day in Patients With Diabetes and Acute Coronary Syndrome
Acronym
ANDAMAN
Condition
Diabetes Mellitus
Condition
Acute Coronary Syndrome
Condition
Obesity
Intervention (Drug)
Novel strategy Aspirin
Intervention (Drug)
Conventional strategy Aspirin
Lead sponsor
Assistance Publique - Hôpitaux de Paris (class: other)
Collaborator
Bayer (class: industry)

Record details

Record id
cardio:ct-nct02520921
Content hash
3f5f0fe088de5304908714f1be481fc35e2722e810ad7cd12982e287706f03d4